Cancer Immunotherapy & Biofluid Biopsies 2016

Home
|
Posters
|

Keynote Speakers

Konstantinos Aprilakis Biotechnology Equity Research, JMP Securities, LLC	Ellen Beasley Senior Vice President, Genomic Health Inc	Christine Biron Esther Elizabeth Brintzenhoff Professor of Medical Science, Professor of Molecular Microbiology and Immunology, Brown University	E Antonio Chiocca Professor and Chairman, Department of Neurosurgery, Brigham and Women's Hospital/Harvard Medical School	David Fabrizio Leader, Cancer Immunotherapy, Foundation Medicine	Gordon Freeman Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School
Tony Godfrey Associate Chair – Research, Department of Surgery, Boston University Medical Center	David Hafler William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology, Yale University	Malini Harigopal Associate Professor, Dept of Pathology, Breast and Cytopathology, Yale University	Shana Kelley Professor, University of Toronto	Fred Kramer Professor of Microbiology, Biochemistry & Molecular Genetics, New Jersey Medical School Rutgers University	Cloud Paweletz Head of the Translational Research Laboratory, Dana Farber Cancer Institute
Johan Skog Chief Scientific Officer, Exosome Diagnostics Inc	Paul Song Chief Medical Officer, Cynvenio Biosystems	Gary S Stein Professor and Chairperson, Department of Biochemistry, Director, University of Vermont Cancer Center	AmirAli Talasaz Co-Founder, President & COO, Guardant Health	Abraham Tzou Medical Officer, Food and Drug Administration (FDA/CDRH)

Overview

Cancer Immunotherapy represents a portfolio of approaches aimed at deploying the immune system against tumor targets in vivo. There is a growing body of scientific and clinical evidence that these approaches are yielding clinically-actionable strategies for cancer treatment.

Biofluid Biopsies represents the harvest of circulating biomarkers to monitor progression of disease especially in cancer. The minimally-invasive means of capture of circulating-free DNA (cfDNA), circulating tumor cells (CTCs), circulating proteins and circulating extracellular vesicles (EVs) represents a new paradigm for longitudinal monitoring of disease and therapy progression.

Cancer Immunotherapy & Biofluid Biopsies 2016 brings together the key opinion leaders in the immunotherapy and tumor immunology fields to address the most up-to-date strategies for immune therapy and means by which immunotherapies may be rationally-combined with more traditional anti-cancer therapeutics. This field is converging with biofluid biopsies/liquid biopsies and therefore this conference brings together these two disciplines as they are co-evolving.

This conference also addresses biomarkers and companion diagnostics (CDx) which can be utilized to "target patient populations" suitable for immunotherapies.

Presentations from researchers and clinician-scientists at this conference discuss the most recent themes and clinical data.

Agenda Topics

Biomarkers & Companion Diagnostics for Immunotherapy
Checkpoint and Non-Checkpoint Immunotherapies
Chimeric Antigen Receptor (CAR) T-Cells in Cancer Immunotherapy

CAR T-Cell Design

Circulating Biomarkers for Monitoring Disease Progression and Treatment Outcomes

Circulating Cell-Free DNA (cfDNA)
Circulating Tumor Cells (CTCs)
Extracellular Vesicles (EVs): Exosomes and Microvesicles as Circulating Biomarker Carriers

Combination Cancer Immunotherapy
Costimulatory Molecules for Immunological Activation & Therapeutic Intervention

CD28 and others

Immunomodulatory Antibodies
Liquid Biopsies for Minimally-Invasive Diagnostics
Natural Killer (NK) Cells in Cancer Immunotherapy
New and Emerging Targets for Immunological Intervention in Cancer

PD-1/PDL-1

Oncolytic Viruses as Cancer Immunotherapeutics
Peptide Vaccines
Preclinical Animal Models for Immuno-Oncology
Small Molecules in Cancer Immune Therapy

Clinical Results
Mechanisms of Action

Targeting Signaling Pathways in Cancer as Therapeutic Intervention
Targeting the Tumor Microenvironment

Sponsorship and Exhibition Opportunities

Jeff Fan, Exhibition Manager
jeff@selectbioconferences.com
+1-510-857-4865

Distinguished Faculty

Stephanie Dougan, Assistant Professor, Dana-Farber Cancer Institute
Nikhil Joshi, Assistant Professor of Immunobiology, Yale University
Alain Charest, Associate Professor, Beth Israel Deaconess Medical Center, Cancer Research Institute, Department of Medicine, Harvard Medical School
Brian Dougherty, Executive Director, Translational Genomics, Oncology IMED, AstraZeneca R&D
Thomas-Oliver Kleen, Executive VP Immune Monitoring, Epiontis GmbH
Francesco Marangoni, Instructor in Medicine, Massachusetts General Hospital/Harvard Medical School
Leonora Balaj, Instructor in Neurosurgery, Mass General Hospital (MGH)/Harvard Medical School
Galina Gabriely, Instructor, Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital
Stephen Kirk, Non-Clinical Immunotoxicologist, Covance Laboratories Ltd
Brian Miller, Oncology Fellow, Dana-Farber Cancer Institute
Louis Messina, Professor and Chief Division od Vascular and Endovascular Surgery, Vice Chair Department of Surgery, University of Massachusetts Medical School
Raymond Welsh, Professor Emeritus, University of Massachusetts Medical School
Carmen Gerlach, Researcher, Harvard Medical School

Corporate Sponsors	Web Sponsors	Offical Journal Partner	Networking